FDA to Remove Warning Labels for Hormone Therapies

Overview of the Decision

The Food and Drug Administration (FDA) has announced plans to eliminate warning labels associated with hormone therapies for menopausal women. This decision marks a significant shift from longstanding cautionary messages regarding potential risks of cancer and heart disease linked to these treatments.

Details of the Announcement

In a statement released on Monday, the FDA indicated its intention to remove “boxed” warnings for all hormone replacement therapies (HRTs). This announcement coincided with a press conference held by the U.S. Department of Health and Human Services (HHS) and an op-ed published by FDA Commissioner Martin Makary in the Wall Street Journal. The agency based its decision on a comprehensive review of scientific literature, input from an expert panel convened in July, and feedback received during a public comment period.

Statements from Officials

HHS Secretary Robert F. Kennedy Jr. expressed optimism about the change, stating, “Millions of women were told to fear the very therapy that could have given them strength, peace and dignity through one of life’s most difficult transitions, menopause. That ends today.” HRT is known to alleviate vasomotor symptoms, such as hot flashes, experienced by women undergoing menopause, but has been underprescribed due to severe “black box” warnings from the FDA.

Historical Context of the Warnings

The current labeling for HRT includes warnings against using estrogen for the prevention of cardiovascular disease or dementia. These labels originated from findings of the Women’s Health Initiative study, which assessed the effects of estrogen plus progestin in postmenopausal women. The study was halted in 2002 due to an identified increased risk of breast cancer and heart disease, and a subsequent study evaluating estrogen alone was also stopped early in 2004 due to a higher risk of stroke.

Research Findings and Medical Opinions

Subsequent research has produced mixed results, indicating potential benefits of HRT for alleviating hot flashes and night sweats, as well as possible positive effects on heart health and bone density. This has led to an ongoing debate regarding the risks and benefits of HRT. While some medical associations advocate for its broader use, they still acknowledge the associated risks and recommend discussions between patients and their doctors.

Commissioner Makary’s Perspective

Commissioner Makary has long criticized the existing safety warnings for HRT and has argued for broader acceptance of the therapy. In his 2024 book “Blind Spots,” he raised questions about the evidence linking HRT to cancer and suggested that the long-term benefits of HRT have been largely overlooked. The 12-member panel he convened in July shared similar views, advocating for an update to HRT labeling.

Concerns About the Review Process

Despite the favorable outcomes from the expert panel, the process of arriving at the FDA’s decision was unconventional. The July panel meeting was informal, in contrast to the rigorous assessments typically conducted by FDA advisory committees, which evaluate new safety data. Public comments were only solicited after the panel’s discussions. When asked about the absence of an advisory panel, Makary defended the decision, stating that traditional committees can be “bureaucratic, long, often conflicted and very expensive,” and emphasized the value of spontaneous discussions among medical experts.

Additional Approvals

In conjunction with this announcement, the FDA also approved two new treatments: a generic version of Premarin for menopausal symptoms and a non-hormonal therapy for managing hot flashes.